Addex Therapeutics Ltd (ADXN) Quality Analysis

ADXN GoodMoat Verdict

Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.

Run Stock X-Ray →

ADXN Profitability

Profitability trend analysis coming soon

ADXN Growth

Growth trend analysis coming soon

ADXN Financial Health

Financial health indicators coming soon

ADXN Quality & Fundamental Analysis

Addex Therapeutics Ltd (ADXN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Addex Therapeutics Ltd's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.

Addex Therapeutics Ltd has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of -3830.01% and a return on equity (ROE) of -67.24%. Return on assets (ROA) stands at -60.94%.

The debt-to-equity ratio is 0.00, with a current ratio of 4.42. Operating margin is -671.94%.

GoodMoat's quality analysis uses AI-powered insights to evaluate whether Addex Therapeutics Ltd is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.